Related Experiment Video

Updated: Aug 16, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

[Transient neonatal myasthenia gravis]

V Váradi1, A Nagy, I György

  • 1Debreceni Orvostudományi Egyetem, Gyermekklinika, Budapest.

Orvosi Hetilap
|February 19, 1995
PubMed

Insights

Transient myasthenia gravis in newborns is linked to maternal polyhydramnios. Treatment involves blood exchange transfusions and pyridostigmine, offering effective symptom management for infants.

Area of Science:

  • Neonatal Medicine
  • Neurology
  • Pediatrics

Context:

  • Transient myasthenia gravis presents in fetal or early neonatal periods.
  • Maternal polyhydramnios is identified as a risk factor correlating with symptom severity in affected newborns.

Purpose:

  • To report on experiences with neonatal transient myasthenia gravis.
  • To investigate the correlation between maternal polyhydramnios and neonatal disease severity.
  • To outline effective treatment strategies for this condition.

Summary:

  • Transient myasthenia gravis (TMG) in newborns, developing in fetal or early neonatal stages, shows a direct correlation with maternal polyhydramnios, increasing disease severity.
  • Treatment regimens included blood exchange transfusions and pyridostigmine (Mestinon) for 2-10 weeks.
  • Five cases of TMG responded well to blood exchange transfusions, highlighting its efficacy.

Impact:

  • Highlights transient myasthenia gravis as a potential cause of respiratory distress in neonates.
  • Emphasizes the importance of considering TMG in infants with unexplained respiratory inadequacy.
  • Provides evidence for effective treatment options, including blood exchange transfusions and pyridostigmine.

More Related Videos

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats07:56

Transient Middle Cerebral Artery Occlusion Model of Neonatal Stroke in P10 Rats

Published on: April 21, 2017

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models04:30

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

Related Concept Videos

Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...